Hello, Sign in
My Account
My Account
New customer? Start here
| Catalog # | Availability | Size | Quantity | Unit Price | Save For Later Wish List | |
|---|---|---|---|---|---|---|
| RCP0842-2 | 7 days | 2 µg | $120.00 |
Select product before adding to cart
|
||
| RCP0842-10 | 7 days | 10 µg | $290.00 | |||
| RCP0842-100 | 7 days | 100 µg | $1,600.00 |
Product Overview | |
| Name | FCGRT Human |
|---|---|
| Description | |
| Fc Fragment Of IgG Receptor And Transporter Human Recombinant | |
| Accession (Primary) | P55899 |
| Synonyms | |
| IgG receptor FcRn large subunit p51, FcRn, IgG Fc fragment receptor transporter alpha chain, Neonatal Fc receptor, Fcgrt, Fcrn. | |
| Introduction | |
| Fc Fragment Of IgG Receptor And Transporter also known as FCGRT is a transmembrane glycoprotein with structural homology to MHC class 1 proteins. FCGRT is widely expressed in endothelial and epithelial cells and takes a vital part in IgG homeostasis. Moreover, FCGRT is expressed in neutrophils in addition myeloid antigen presenting cells. FCGRT can enhance IgG-meditated phagocytosis as well as antigen presentation by heses cells, however it promotes the degradation of opsonizing IgG rather than returning it to the circulation. | |
| Source | |
| Sf9, Baculovirus cells. | |
| Physical Appearance | |
| Sterile filtered colorless solution. | |
| Formulation | |
| FCGRT protein solution (0.5mg/ml) contains Phosphate buffered saline (pH7.4) and 10% glycerol. | |
| Stability | |
| Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Avoid multiple freeze-thaw cycles. | |
| Purity | |
| Greater than 85.0% as determined by SDS-PAGE. | |
| Amino acid sequence | |
| ADP SETRPPL MYHLTAVSNP STGLPSFWAT GWLGPQQYLT YNSLRQEADP CGAWMWENQV SWYWEKETTD LKSKEQLFLE ALKTLEKILN GTYTLQGLLG CELASDNSSV PTAVFALNGE EFMKFNPRIG NWTGEWPETE IVANLWMKQP DAARKESEFL LNSCPERLLG HLERGRRNLE WKEPPSMRLK ARPGNSGSSV LTCAAFSFYP PELKFRFLRN GLASGSGNCS TGPNGDGSFH AWSLLEVKRG DEHHYQCQVE HEGLAQPLTV DLDSSARSS H HHHHH. | |
| Precautions | |
| FCGRT Human is for research use only and not for use in diagnostic or therapeutic procedures. | |
Target Information: ( P55899 ) | |
Background |
Applications in Drug Delivery and Therapy: The unique ability of FCGRT to transport immunoglobulins has spurred investigations into its potential applications in drug delivery. FCGRT Human Recombinant is being explored as a tool to improve the pharmacokinetics of therapeutic antibodies, enhancing their stability and extending their half-life in circulation. This holds significant implications for the development of antibody-based therapies for a range of diseases, including autoimmune disorders and cancer. Modulation of Immune Responses: Beyond its role in immunoglobulin transport, FCGRT is implicated in the modulation of immune responses. FCGRT Human Recombinant studies have unveiled its interactions with immune cells and its potential influence on the activation and regulation of the immune system. This dual role positions FCGRT as a key player not only in passive immunity but also in the dynamic orchestration of immune responses. Challenges and Future Directions: While the potential of FCGRT Human Recombinant in drug delivery is promising, challenges persist. Fine-tuning its applications, understanding its interactions with diverse antibodies, and optimizing strategies for therapeutic use are critical considerations for translational success. Additionally, deciphering the intricate balance between immunoglobulin transport and immune modulation is an active area of investigation. FCGRT Human Recombinant emerges as a sentinel in the realm of immunoglobulin transport and drug delivery, offering a controlled platform for scientific exploration. Its structural insights, immunoglobulin transport functions, and therapeutic applications position it as a key player in the evolving landscape of biopharmaceuticals. As researchers continue to delve into the molecular intricacies of FCGRT, they not only enhance our understanding of immunoglobulin transport but also pave the way for transformative advancements in drug delivery and antibody-based therapies, shaping the future of precision medicine and targeted therapeutics. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from ADMEbio to advance their research.
Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
Thank you,
ADMEbio Team
ADMEbio welcomes feedback from our customers.
Thank you,
ADMEbio Team
